VBL Therapeutics loses 64% of its value in few hours following disappointing Phase-III results

Israel-based VBL Therapeutics has lost 64% of its value in few hours after it was announced that its VB-111 investigational therapy, in combination with Avastin’s bevacizumab has not demonstrated benefits as compared to Avastin’s bevacizumab alone in the Phase-III Globe clinical trial conducted on patients with glioblastoma (brain cancer).  VBL Therapeutics some time before had announced a marketing agreement with Japan-based NanoCarrier for VB-111, which was expected to fetch the recently established company approximately $100m.

(Source: VBL Therapeutics)